2 Top Ways to Fight Inflation in 2022

What if inflation persists in spite of the rapid-fire rate hikes? In such a scenario, savers could have a real problem on their hands.

| More on:
stock market

Image source: Getty Images

Inflation was supposed to be transitory (whatever that means), according to the U.S. Federal Reserve chair. Here we are in 2022, and inflation isn’t just showing signs of cooling off; it’s creeping higher, with amplification across certain classes of goods. Indeed, COVID shortages and all the sort are doing no favours to central banks who would love if inflation were to back down and fall towards that 2% target rate.

Unfortunately, the inflation genie is hard to get back in the bottle once it’s been let out. In prior pieces, I’d warned that persistent inflation was a cause for concern, and that investors should have a plan to fight it off. The costs of holding cash are at a high point, with rampant inflation, which actually surpassed 6% in the United States. Undoubtedly, a trio of rate hikes could help put inflation back in its place (the 2-3% range). But what if inflation persists in spite of the rapid-fire rate hikes? In such a scenario, savers could have a real problem on their hands.

Inflation: Persistent or transitory?

That’s why it’s unwise to simply conclude that inflation is transitory, not worth worrying about, and continuing as planned, especially with overly conservative investors with more cash on the sidelines than most others. Yes, it’s good to hold cash in any environment. Market crashes and corrections happen, and dry powder is needed to take advantage of the opportunities that arise. Steep plunges call for liquidity, as the best bargains can evaporate, as they did in the 2020 stock market crash!

At the same time, inflation is an insidious tax on those who hoard cash. It’s good to be conservative and prudent. But it’s a bad idea to neglect the wealth-eroding effects of inflation. Simply put, cash is less of a safe-haven asset, and those overweight in its via savings accounts should look to put money to work in securities that can help one move through this bout of inflation. Transitory or persistent, investors should be ready to deal with any type of inflationary environment through 2022 and beyond.

In terms of inflation fighters, here are two plays.

Gold and silver

First up, we have precious metals plays. Gold is historically a magnificent store of wealth when inflation comes in rough. Silver is more prone to cyclical swings based on demand but is still an intriguing option, especially after its latest selloff. Currently, gold and silver are in a funk, and their miners are in a world of pain.

While bullion, ETFs, and streamers may be an intriguing way to play gold and silver, I’d argue that the miners, which can be viewed as a leveraged way to play the precious metals they mine, are a great bet here.

Barrick Gold (TSX:ABX)(NYSE:GOLD) is a top-tier gold miner that’s stuck in a rut. In 2022, gold could creep higher as the speculation is drained out of this market, both in high-multiple equities and various cryptocurrencies. To make ABX stock even better, you’re getting a nearly 2% dividend yield while you wait. Such a yield can help you better dodge and weave through inflation, although it’s the capital gains potential that can really help you gain a leg up on inflation.

Dividend stocks

Equities are a great way to combat inflation, but you’ve got to make sure you’re in the right equities at proper valuations. Think cheap dividend stocks like Barrick Gold or Enbridge. Such battered plays boasts larger yields after they’ve suffered nasty declines. In a market where growth is being punished, and value is mostly being spared, dividend stocks are a solid bet. Not only can you avoid feeling a brunt of the damage from the tech wreck, but dividends will help you fight inflation.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. The Motley Fool recommends Enbridge.

More on Investing

healthcare pharma
Investing

Down 15% Since Earnings: Is WELL Health a Good Stock to Buy?

Despite the near-term weakness, WELL Health offers excellent buying opportunities for long-term investors, given the expanding addressable markets and attractive…

Read more »

clock time
Investing

Is It Too Late to Buy Costco Stock Now?

Costco stock has rallied almost 2,000% in the last 20 years, but the ride is not over yet as international…

Read more »

rail train
Investing

CN and CP Stocks Are Way Too Cheap for What They’re Worth

CN Rail (TSX:CNR) and CP Rail (TSX:CP) are great wide-moat kings to load up on if you're looking to thrive…

Read more »

Man holding magnifying glass over a document
Tech Stocks

Lightspeed Stock Could Be Turning a Corner

Lightspeed Commerce (TSX:LSPD) is making strides towards operating profitability.

Read more »

protect, safe, trust
Dividend Stocks

RBC Stock: Defensive Bank for Safe Dividends and Returns

Royal Bank of Canada (TSX:RY) is the kind of blue-chip stock that investors can buy and forget.

Read more »

edit Balloon shaped as a heart
Stocks for Beginners

My 5 Favourite Stocks to Buy Right Now

These companies continue to be some of my favourite stocks on the TSX today, with all proving to be major…

Read more »

Community homes
Dividend Stocks

TSX Real Estate in April 2024: The Best Stocks to Buy Right Now

High interest rates are creating enticing value in real estate investments. Here are two Canadian REITS to consider buying on…

Read more »

edit Businessman using calculator next to laptop
Investing

Is Now the Right Time to Buy BCE Stock? Here’s My Take

BCE (TSX:BCE) stock only seems to go lower these days, but there is hope in sight for patient value hunters.

Read more »